Recruiting studies: Malaria Vivax

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Primaquine for Vivax Malaria in G6PD Intermediate and Deficient Cases.
Phase 4 · 4 location(s) · Menzies School of Health Research · NCT07468513 ACT vs CQ With Tafenoquine for P. Vivax Mono-infection
Phase 4 · 1 location(s) · Shoklo Malaria Research Unit · NCT05788094 Investigating the Pharmacokinetics of Tafenoquine in Healthy Papua New Guinean Children
Phase 4 · 1 location(s) · Curtin University · NCT07052162 Induced Blood-Stage Malaria in Healthy Malaria-Naive Adults to Assess the Safety and Infectivity of Plasmodium Vivax Cha
Phase 1 · 1 location(s) · National Institute of Allergy and Infectious Diseases (NIAID · NCT06607003 Plasmodium Immunotherapy for Advanced Malignant Solid Tumors
Phase 1/Phase 2 · 1 location(s) · CAS Lamvac Biotech Co., Ltd. · NCT04165590 An Interventional Study to Compare the Efficacy and Safety of Tafenoquine (TQ) and Primaquine (PQ) When Either Are Taken
Phase 3 · 4 location(s) · GlaxoSmithKline · NCT06666491 Clinical Study to Assess Minimum Mosquito Bites for P. Vivax Infection in Thai Adults
NA · 1 location(s) · University of Oxford · NCT07257965 A Revised Tafenoquine Dose to Improve Radical Cure for Vivax Malaria
Phase 3 · 4 location(s) · Menzies School of Health Research · NCT06148792 Serological Testing and Treatment for Plasmodium Vivax Malaria: a Trial in Ethiopia and Madagascar
Phase 3 · 2 location(s) · London School of Hygiene and Tropical Medicine · NCT06923592 A Controlled Human Vivax Malaria Infection Study Through Inoculation of Infected Erythrocytes
NA · 1 location(s) · University of Oxford · NCT05071079 Southeast Asia Dose Optimization of Tafenoquine
Phase 4 · 5 location(s) · University of Oxford · NCT04704999 FocaL Mass Drug Administration for Vivax Malaria Elimination
Phase 3 · 1 location(s) · University of California, San Francisco · NCT05690841 Plasmodium Immunotherapy for Advanced Cancers
Phase 1/Phase 2 · 1 location(s) · CAS Lamvac Biotech Co., Ltd. · NCT03375983

Look up another condition

Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.